DiaMedica Therapeutics (DMAC)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	4.13 mm	4.13 mm	4.13 mm	4.13 mm	4.13 mm	4.13 mm
Cash burn (monthly)	3.31 mm	(no burn)	2.29 mm	2.01 mm	1.49 mm	1.62 mm
Cash used (since last report)	16.77 mm	n/a	11.62 mm	10.18 mm	7.55 mm	8.21 mm
Cash remaining	-12.63 mm	n/a	-7.49 mm	-6.04 mm	-3.41 mm	-4.08 mm
Runway (months of cash)	-3.8	n/a	-3.3	-3.0	-2.3	-2.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

DMAC institutional ownership history Ownership history

38.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	28	37	-24.3%
Opened positions	7	5	+40.0%
Closed positions	16	3	+433.3%
Increased positions	4	9	-55.6%
Reduced positions	3	9	-66.7%

13F shares	Current	Prev Q	Change
Total value	9.61 bn	14.99 bn	-35.9%
Total shares	16.61 mm	19.37 mm	-14.3%
Total puts	0.00	1.00 k	EXIT
Total calls	0.00	1.30 k	EXIT
Total put/call ratio	–	0.8	–

Largest owners	Shares	Value	Change
TomEnterprise AB	4.33 mm	$18.39 mm	0.0%
Trill Ab	4.02 mm	$17.09 mm	0.0%
Private AB TomEqt	2.86 mm	$3.86 mm	0.0%
Dialectic Capital Management	2.17 mm	$6.41 mm	0.0%
Vanguard	1.05 mm	$4.40 bn	+3.1%
Xiao Zhenyu	929.71 k	$6.37 mm	0.0%
Bleichroeder	382.32 k	$1.60 bn	0.0%
Geode Capital Management	306.96 k	$1.29 bn	+29.6%
LPL Financial	140.50 k	$588.70 mm	+702.9%
NTRS Northern Trust	120.29 k	$504.02 mm	-0.1%

Largest transactions	Shares	Bought/sold	Change
Cooperman Leon G	0.00	-1.40 mm	EXIT
First Manhattan	0.00	-839.08 k	EXIT
Paragon Associates & Paragon Associates Ii Joint Venture	0.00	-482.61 k	EXIT
LPL Financial	140.50 k	+123.00 k	+702.9%
BlackRock	107.79 k	+107.79 k	NEW
Aristides Capital	0.00	-106.33 k	EXIT
BLK BlackRock	0.00	-105.30 k	EXIT
MS Morgan Stanley	0.00	-86.20 k	EXIT
Geode Capital Management	306.96 k	+70.07 k	+29.6%
STT State Street	0.00	-68.73 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DMAC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Feb 25	O'Connor Daniel J.	Stock Option Common Stock	Grant	Acquire A	No	No	6.61	64,242	424.64 k	64,242
13 Feb 25	Giuffre Randall Michael	Voting Common Shares, no par value per share	Option exercise	Acquire M	No	No	3.65	5,000	18.25 k	392,412
13 Feb 25	Giuffre Randall Michael	Voting Common Shares, no par value per share	Option exercise	Acquire M	No	No	2.11	12,000	25.32 k	387,412
13 Feb 25	Giuffre Randall Michael	Stock Option Common Shares	Option exercise	Dispose M	No	No	3.65	5,000	18.25 k	0
13 Feb 25	Giuffre Randall Michael	Stock Option Common Shares	Option exercise	Dispose M	No	No	2.11	12,000	25.32 k	0
2 Jan 25	Charles Pauling Semba	Voting Common Shares, no par value per share	Grant	Acquire A	No	No	5.34	5,290	28.25 k	44,608
2 Jan 25	Giuffre Randall Michael	Voting Common Shares, no par value per share	Grant	Acquire A	No	No	5.34	10,861	58.00 k	375,412

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

24 Feb 25

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors,

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

20 Feb 25

Scientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

10 Feb 25

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will present at

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

3 Dec 24